Safety and efficacy of BAY 94-9027, an extended-half-life factor VIII, during minor surgical procedures in patients with severe haemophilia A

Authors: Santagostino E; Lalezari, S; Reding, MT.; Ducore, J; Ng, HJ; Poulsen, LH.; Michaels, LA.; Linardi, C.

Affiliations: Foundation IRCCS Ca’ Granda, Maggiore Hospital Policlinico A. Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy ; Israel National Hemophilia Center, Chaim Sheba Medical Center, Tel Hashomer, Israel ; Sackler School of Medicine, Tel-Aviv University, Tel Hashomer, Israel; Center for Bleeding and Clotting Disorders, University of Minnesota Medical Center, Minneapolis, MN, USA ; Hemophilia Treatment Center, UC Davis Medical Center, Sacramento, CA, USA ; Department of Haematology, Singapore General Hospital, Singapore ; The Haemophilia Centre, Aarhus University Hospital, Aarhus, Denmark; Bayer, Whippany, NJ, USA.

Publication: Haemophilia; May 2021

Abstract: In patients with haemophilia A, minor surgical interventions are vital for improving well-being and may prevent major surgical procedures. However, the risk of bleeding in minor surgery may be higher than in major surgery. Local haemostasis may not be ensured with suturing, cautery or pressure application, and minor procedures may be performed without the involvement of an experienced multidisciplinary team.1 Individualised haemostatic therapy should be used to maintain appropriate levels of factor VIII (FVIII) in haemophilia A patients during the perioperative period for all surgical procedures to prevent excessive bleeds. However, FVIII monitoring is seldom performed during minor surgeries, warranting prior knowledge of FVIII products.